TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27457255

Group type: EXPERIMENTAL
Intervention: High-dose implant
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low-dose implant
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Explanted eyes
Number of subjects: 36
Study: 24495042

Group type: EXPERIMENTAL
Intervention: Cetuximab with grade 2+ rash
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab with grade 0/1 rash
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab with KRAS mutated tumours (any rash grade)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 22999098

Group type: EXPERIMENTAL
Intervention: Kinesiotherapy (KIN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40
Study: 20179212

Group type: EXPERIMENTAL
Intervention: Siltuximab 6 mg/kg every 2 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Siltuximab 9 mg/kg every 3 weeks
Number of subjects: 68
Study: 17296972

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 611

Group type: COMPARATOR
Intervention: MBS
Number of subjects: 611
Study: 16224086

Group type: EXPERIMENTAL
Intervention: Active treatment group from phase III ischemic stroke therapy trials
Number of subjects: 6
Study: 12392866

Group type: EXPERIMENTAL
Intervention: Overnight mail delivery
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: No certificate of appreciation
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Timing of administration close to study closeout
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Survey distribution methods
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Respondents characteristics
Number of subjects: 664

Group type: COMPARATOR
Intervention: Nonrespondents characteristics
Number of subjects: 664
Study: 9920089

Group type: EXPERIMENTAL
Intervention: recombinant human FSH (r-hFSH)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: low dose recombinant human LH (r-hLH) (150 IU, twice daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: high dose recombinant human LH (r-hLH) (375 IU, twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: saline
Number of subjects: 24
Study: 7661074

Group type: EXPERIMENTAL
Intervention: Combined oral anticoagulant and antiplatelet therapy
Number of subjects: 5
Study: 2292620

Group type: EXPERIMENTAL
Intervention: Culturally sensitive modeling therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7024156

Group type: EXPERIMENTAL
Intervention: mianserin (10 mg nocte)
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: mianserin and placebo
Number of subjects: 45
Study: 31176788

Group type: EXPERIMENTAL
Intervention: 5,000 ppm fluoridated dentifrice
Number of subjects: 345

Group type: COMPARATOR
Intervention: 1,450 ppm fluoridated dentifrice
Number of subjects: 345
Study: 28091349

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 25951907

Group type: EXPERIMENTAL
Intervention: Team Awareness (TA) intervention, 8 hours duration
Number of subjects: 325

Group type: COMPARATOR
Intervention: One-hour wellness talk (Control)
Number of subjects: 325
Study: 24188573

Group type: EXPERIMENTAL
Intervention: Multi-level intervention to reduce antibiotic prescribing
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Exam room poster depicting a diagnostic algorithm
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: General intervention strategies
Number of subjects: 29
Study: 21127308

Group type: EXPERIMENTAL
Intervention: Etilefrine
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 19167961

Group type: EXPERIMENTAL
Intervention: Immediate group intervention (n=55)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Delayed group intervention (n=48)
Number of subjects: 103
Study: 17377238

Group type: EXPERIMENTAL
Intervention: LapSim System (virtual reality laparoscopic simulator)
Number of subjects: 2

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 2
Study: 15497908

Group type: EXPERIMENTAL
Intervention: Drospirenone (1, 2 or 3 mg) combined with estradiol (1 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11150476

Group type: EXPERIMENTAL
Intervention: Early blind subjects
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sighted control subjects
Number of subjects: 5
Study: 9130150

Group type: EXPERIMENTAL
Intervention: Shoulder protraction measurement
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Thoracolumbar rotation measurement
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Between-rater reliability
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Within-rater reliability
Number of subjects: 55
Study: 7959187

Group type: EXPERIMENTAL
Intervention: Enteric coated tablets
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Gelatin capsules
Number of subjects: 23
Study: 3496848

Group type: EXPERIMENTAL
Intervention: Cefoxitin, piperacillin, cefoperazone, and aztreonam administered intravenously for 9 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefoxitin and piperacillin
Number of subjects: 20
Study: 29891250

Group type: EXPERIMENTAL
Intervention: Nicorandil (2mg)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Saline (2mL)
Number of subjects: 170
Study: 28554818

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NIV in temperate conditions (22°C, 40% relative humidity)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NIV in hot-humid conditions (32°C, 70% relative humidity)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NIV use
Number of subjects: 16

Group type: COMPARATOR
Intervention: No NIV
Number of subjects: 16
Study: 25220555

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenous)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl solution)
Number of subjects: 53
Study: 23802352

Group type: EXPERIMENTAL
Intervention: Intervention A (weekly training courses with therapy sessions)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intervention B (modular and high structured small group training)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 34
Study: 20812020

Group type: EXPERIMENTAL
Intervention: 2 l PEG combined with 36 mg senna glycosides in tablets
Number of subjects: 490

Group type: COMPARATOR
Intervention: 4 l PEG
Number of subjects: 490
Study: 19929645

Group type: EXPERIMENTAL
Intervention: On-site provision of implants and IUDs at Site B
Number of subjects: 62

Group type: COMPARATOR
Intervention: Referral to public family planning services at Site A
Number of subjects: 62
Study: 17134598

Group type: EXPERIMENTAL
Intervention: Issuing karyotype results on a prespecified fixed date
Number of subjects: 226

Group type: COMPARATOR
Intervention: Issuing karyotype results as soon as they became available
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Issuing early results from a rapid molecular test for the most common chromosomal abnormalities
Number of subjects: 226

Group type: COMPARATOR
Intervention: Receiving only the full karyotype results
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Anxiety at the 1-month follow-up
Number of subjects: 226
Study: 15255284

Group type: EXPERIMENTAL
Intervention: 30 mg ospemifene
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 60 mg ospemifene
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 90 mg ospemifene
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 11750186

Group type: EXPERIMENTAL
Intervention: Nimodipine (90 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9259934

Group type: EXPERIMENTAL
Intervention: Oral erythromycin for 7 days in addition to routine prophylactic intravenous ampicillin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ampicillin alone
Number of subjects: 51
Study: 8315574

Group type: EXPERIMENTAL
Intervention: Zidovudine sensitivity (IC50 > 1 microM) in progressors
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Syncytium-inducing (SI) phenotype in progressors
Number of subjects: 68

Group type: COMPARATOR
Intervention: Zidovudine therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: SI phenotype
Number of subjects: 68
Study: 3687352

Group type: EXPERIMENTAL
Intervention: Group I: microaggregate‐poor erythrocyte concentrate (SAGM‐ERC) plus 3% dextran‐60 as plasma substitute, postoperative analgesia with intramuscular ketobemidone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group II: microaggregate‐poor erythrocyte concentrate (SAGM‐ERC) plus 3% dextran‐60, prolonged epidural anesthesia with 0.5% bupivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group III: non‐frozen stored plasma plus SAGM‐ERC, postoperative analgesia with ketobemidone
Number of subjects: 45
Study: 30391318

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 79
Study: 28422886

Group type: EXPERIMENTAL
Intervention: ETS at T2 level (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ETS at T3 level (group B)
Number of subjects: 50
Study: 25936543

Group type: EXPERIMENTAL
Intervention: Coping skills intervention
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33
Study: 23638702

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 0
Study: 20878293

Group type: EXPERIMENTAL
Intervention: Tailored print letters
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: Motivational telephone calls
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: Combined tailored letters and motivational calls
Number of subjects: 1629

Group type: COMPARATOR
Intervention: Control group (no information)
Number of subjects: 1629
Study: 19955524

Group type: EXPERIMENTAL
Intervention: CT screening in round one
Number of subjects: 7557

Group type: EXPERIMENTAL
Intervention: CT screening in round two
Number of subjects: 7557
Study: 17445811

Group type: EXPERIMENTAL
Intervention: rFSH
Number of subjects: 66

Group type: COMPARATOR
Intervention: CC
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both interventions (CC and rFSH)
Number of subjects: 66
Study: 15456082

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 1304

Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 1304

Group type: EXPERIMENTAL
Intervention: Gynaecomastia resolution
Number of subjects: 1304

Group type: EXPERIMENTAL
Intervention: Hormone levels
Number of subjects: 1304
Study: 11178336

Group type: EXPERIMENTAL
Intervention: Streptogramins (quinupristin/dalfopristin and RPR-106972)
Number of subjects: 0
Study: 10207592

Group type: EXPERIMENTAL
Intervention: Cefepime (2 g x 2/day) + Amikacin (7.5 mg.kg‐1 x 2/day)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Ceftazidime (2 g x 3/day) + Amikacin (7.5 mg.kg‐1 x 2/day)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Cefepime + Amikacin
Number of subjects: 275

Group type: COMPARATOR
Intervention: Ceftazidime + Amikacin
Number of subjects: 275
Study: 8549245

Group type: EXPERIMENTAL
Intervention: 8 Gy radiation therapy (single fraction)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 12 Gy radiation therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 18 Gy radiation therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 24 Gy radiation therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Natural history data of subfoveal age-related CNV
Number of subjects: 40
Study: 2755259

Group type: EXPERIMENTAL
Intervention: Clebopride (0.5 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Clebopride (0.75 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Clebopride (1 mg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Clebopride
Number of subjects: 41
Study: 850063

Group type: EXPERIMENTAL
Intervention: Skill Training program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 25
Study: 31638010

Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose 20 mg/kg, administered twice a year for 2 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two doses of azithromycin (6 months apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 doses of azithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 doses of azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original placebo group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azithromycin group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 0
Study: 27936524

Group type: EXPERIMENTAL
Intervention: Generic clopidogrel product (75 mg once daily for 7 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference clopidogrel product (75 mg once daily for 7 days)
Number of subjects: 32
Study: 26348588

Group type: EXPERIMENTAL
Intervention: Combined intervention (psychoeducation plus medication)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment-as-usual (medication alone)
Number of subjects: 61
Study: 23494740

Group type: EXPERIMENTAL
Intervention: 20 g of GaCr milk powder
Number of subjects: 66

Group type: COMPARATOR
Intervention: Milk powder placebo
Number of subjects: 66
Study: 22566310

Group type: EXPERIMENTAL
Intervention: Glutamine (0.5 g/kg/day for 5 days as continuous perfusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18721167

Group type: EXPERIMENTAL
Intervention: WE*CAN intervention delivered during three routine clinic visits by trained 'Health Advisors' over an 8-month period; average of 2.85 intervention sessions.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care comparison group (control group).
Number of subjects: 122
Study: 18162017

Group type: EXPERIMENTAL
Intervention: 2-g E-EPA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15077311

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) at weeks 0, 2, and 6
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 11513820

Group type: EXPERIMENTAL
Intervention: Dawn simulation (1.5 hour dawn signal from 4:30 AM to 6:00 AM peaking at 250 lux)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Bright light therapy (10,000 lux for 30 min, from 6:00 AM to 6:30 AM)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (dim red light, 1.5 hour dawn signal from 4:30 AM to 6:00 AM peaking at 0.5 lux)
Number of subjects: 95
Study: 9742660

Group type: EXPERIMENTAL
Intervention: 10 ppm D4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 0
Study: 7828189

Group type: EXPERIMENTAL
Intervention: 400 mg of riboflavin as a single oral dose for at least 3 months
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 400 mg of riboflavin plus 75 mg of aspirin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study: 2556883

Group type: EXPERIMENTAL
Intervention: RIT 4237 oral rotavirus vaccine
Number of subjects: 28
Study: 1147073

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30857413

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 8178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8178

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment
Number of subjects: 8178

Group type: COMPARATOR
Intervention: Standard blood pressure treatment
Number of subjects: 8178
Study: 28475671

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (dabrafenib 150 mg twice daily + trametinib 2 mg once daily)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Dabrafenib monotherapy
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 423
Study: 26275039

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 1362
Study: 23725524

Group type: EXPERIMENTAL
Intervention: Sour tea (ST)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Green tea (GT)
Number of subjects: 100
Study: 21355147

Group type: EXPERIMENTAL
Intervention: Moxibustion therapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Western medicine (Piracetam tablet)
Number of subjects: 87
Study: 19041440

Group type: EXPERIMENTAL
Intervention: Low dose (LD) OCP (30 mcg EE/150 mcg DSG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very low dose (VLD) OCP (20 mcg EE/150 mcg DSG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EE-only phase (10 mcg EE) in group VLD
Number of subjects: 0
Study: 17953131

Group type: EXPERIMENTAL
Intervention: Drama therapy program
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study: 15372846

Group type: EXPERIMENTAL
Intervention: ezetimibe + statin
Number of subjects: 2382

Group type: COMPARATOR
Intervention: statin
Number of subjects: 2382

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2382

Group type: COMPARATOR
Intervention: statin monotherapy (10, 20, 40 mg/day or 80 mg/day)
Number of subjects: 2382
Study: 11552903

Group type: EXPERIMENTAL
Intervention: Budesonide controlled ileal release 6 mg o.m.
Number of subjects: 143

Group type: COMPARATOR
Intervention: Budesonide controlled ileal release flexible dosing (3, 6 or 9 mg o.m.)
Number of subjects: 143
Study: 9589313

Group type: EXPERIMENTAL
Intervention: Ego threat (subliminal message)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physical threat (subliminal message)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral message (subliminal message)
Number of subjects: 60
Study: 7522721

Group type: COMPARATOR
Intervention: Conventional salvage therapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with subsequent autologous bone marrow transplantation (HDC/ABMT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Irradiation alone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Long-term continuous complete remission (cCR) with salvage therapy
Number of subjects: 88
Study: 3144299

Group type: EXPERIMENTAL
Intervention: +Oxyphenonium
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Racemic Oxyphenonium
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: (-)Oxyphenonium
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31006920

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 181

Group type: COMPARATOR
Intervention: Normal sleep (8–9 hr in bed)
Number of subjects: 181
Study: 28135880

Group type: EXPERIMENTAL
Intervention: EHR changes (G1)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Lecture, no changes in EHR (G2)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lecture and EHR changes (G3)
Number of subjects: 3
Study: 27450232

Group type: EXPERIMENTAL
Intervention: CYP2C19*3 (rs4986893) mutation
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: CES1 rs8192950 mutation
Number of subjects: 377
Study: 23468128

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5‐1 mg/week up to 3.0 mg/week) followed by ketoconazole (200 mg/day to 600 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg/day to 600 mg/day) followed by cabergoline (0.5‐1 mg/week up to 3.0 mg/week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (age-matched patients in prolonged remission after effective neurosurgery for CD)
Number of subjects: 14
Study: 22763497

Group type: EXPERIMENTAL
Intervention: OTC analgesics
Number of subjects: 1734
Study: 18930473

Group type: EXPERIMENTAL
Intervention: Serial sleep deprivation therapy (six nights of total SD within three weeks, separated by nights of recovery sleep)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No sleep deprivation therapy (control group)
Number of subjects: 18
Study: 17086382

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy, 25 min per session, 5 days per week for 3 weeks.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham PEMF therapy, 25 min per session, 5 days per week for 3 weeks.
Number of subjects: 46
Study: 15164859

Group type: EXPERIMENTAL
Intervention: Preventive interventions for children from divorced families
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 218
Study: 11593723

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg.kg‐1, orally, administered 45 min before induction) in Group M
Number of subjects: 109

Group type: COMPARATOR
Intervention: Vehicle in Group C
Number of subjects: 109
Study: 9589658

Group type: EXPERIMENTAL
Intervention: Human recombinant IL-6 (0.5 microgram/kg body weight)
Number of subjects: 16
Study: 8051483

Group type: EXPERIMENTAL
Intervention: beta-hydroxybutyrate during ischemic exercise (low-phosphate state)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: beta-hydroxybutyrate during fructose-induced hepatic ATP breakdown (low-phosphate state)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: beta-hydroxybutyrate during fructose-induced hepatic ATP breakdown (both phosphate conditions)
Number of subjects: 17
Study: 2968548

Group type: EXPERIMENTAL
Intervention: Triptorelin (DTRp6-LH-RH) with human menopausal gonadotropin (long regimen)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Triptorelin (DTRp6-LH-RH) with human menopausal gonadotropin (short regimen)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clomiphene citrate-human menopausal gonadotropin combination without LH-RH analogue (control group)
Number of subjects: 30